EZH2 and lip and oral cavity carcinoma: Previously, Li et al [22] demonstrated the beneficial effects of DZNep, an EZH2 inhibitor, in an in vivo subcutaneous model of OSCC, highlighting its capability to inhibit oral cancer progression through the p16/p21 pathway and epithelial–mesenchymal transition (EMT) modulation.